Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: An observational study

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Patel, Rashmi ^a   Wilson, Robin ^a   Jackson, Richard ^a   Ball, Michael ^a   Shetty, Hitesh ^b   Broadbent, Matthew ^b   Stewart, Robert ^a   McGuire, Philip ^a   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE; ARTICLE; CANNABIS USE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; FREQUENCY; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SEX DIFFERENCE; SINGLE (MARITAL STATUS); CANNABIS SMOKING; ENGLAND; EPIDEMIOLOGY; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; REGISTER; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LOGISTIC MODELS; LONDON; MALE; MARIJUANA SMOKING; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PSYCHOTIC DISORDERS; REGISTRIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84960392938     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009888     Document Type: Article

References (38)

1. United Nations Office on Drugs and Crime. World Drug Report. 2013. http://www.unodc.org/unodc/secured/wdr/wdr2013/World-Drug-Report-2013.pdf
2. Kuepper R, Van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011;342:d738.
3. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
4. Hinton M, Edwards J, Elkins K, et al. Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv Psychiatry 2007;1:259-66.
5. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193:357-63.
6. Barrowclough C, Gregg L, Lobban F, et al. The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophr Bull 2015;41:382-90.
7. Faber G, Smid HG, Van Gool AR, et al. Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. J Clin Psychiatry 2012;73:632-8.
8. Van Dijk D, Koeter MW, Hijman R, et al. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res 2012;137:50-7.
9. Stone JM, Fisher HL, Major B, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 2014;44:499-506.
10. Foti DJ, Kotov R, Guey LT, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010;167:987-93.
11. Knapp M, Andrew A, McDaid D, et al. Investing in recovery: making the business case for effective interventions for people with schizophrenia and psychosis. Lond Rethink Ment Illn 2014.
12. Hides L, Dawe S, Kavanagh DJ, et al. Psychotic symptom and cannabis relapse in recent-onset psychosis. Br J Psychiatry 2006;189:137-43.
13. Lazary J. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Curr Pharm Des 2012;18:4890-6.
14. Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620.
15. Stewart R, Soremekun M, Perera G, et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 2009;9:51. http://www.biomedcentral.com/1471-244X/9/51 http://dx.doi.org/10.1186/1471-244X-9-51
16. Gafoor R, Nitsch D, McCrone P, et al. Effect of early intervention on 5-year outcome in non-affective psychosis. Br J Psychiatry 2010;196:372-6.
17. Chang CK, Hayes R, Broadbent M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010;10:77.
18. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 2011;6:e19590.
19. Wu CY, Chang CK, Hayes RD, et al. Clinical risk assessment rating and all-cause mortality in secondary mental healthcare: the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register. Psychol Med 2012;42:1581-90.
20. Hayes RD, Chang CK, Fernandes AC, et al. Functional status and all-cause mortality in serious mental illness. PLoS ONE 2012;7:e44613.
21. Jackson R. TextHunter. Published Online First: 2 August 2014. http://dx.doi.org/10.5281/zenodo.11122
22. Jackson RG, Ball M, Patel R, et al. TextHunter-a user friendly tool for extracting generic concepts from free text in clinical research. AMIA Annu Symp Proc 2014;2014:729-38.
23. Mental Health Act. Great Britain. London: The Stationery Office, 2007. http://www.legislation. gov. uk/ukpga/2007/12/contents
24. Office for National Statistics. Ethnic group. London: http://www.ons.gov.uk/ons/guide-method/measuring-equality/equality/ethnicnatidentity-religion/ethnic-group/index.html
25. Emsley R, Liu H. PARAMED: Stata module to perform causal mediation analysis using parametric regression models. Stat Softw Components 2013.
26. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173.
27. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods 2013;18:137.
28. Harrison I, Joyce EM, Mutsatsa SH, et al. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 2008;38:79-88.
29. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007;190:515-20.
30. Carr JA, Norman RM, Manchanda R. Substance misuse over the first 18 months of specialized intervention for first episode psychosis. Early Interv Psychiatry 2009;3:221-5.
31. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005;112:141-8.
32. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry 2014;205:1-3.
33. Bloomfield MA, Morgan CJ, Egerton A, et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014;75:470-8.
34. Barbeito S, Vega P, Ruiz De Azúa S, et al. Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry 2013;13:326.
35. González-Pinto A, Alberich S, Barbeito S, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011;37:631-9. http://ovidsp. ovid.com/ovidweb.cgi?T=JS&PAGE=reference& D=medl & NEWS=N&AN=19915168 http://dx.doi.org/10.1093/schbul/sbp126
36. Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet Psychiatry 2016; published online Jan 24. doi:10.1016/S2215-0366 (15) 00363-6
37. Zorrilla I, Aguado J, Haro JM, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand 2015;131:100-10.
38. Schoeler T, Petros N, Behlke I, et al. Cannabis use as a predictor for relapse in first episode psychosis: a three-year follow-up study. Early Interv Psychiatry 2014;8:58.